書誌事項
- タイトル別名
-
- Comparative study on sitafloxacin and levofloxacin in complicated urinary tract infections
この論文をさがす
抄録
The clinical efficacy and safety of sitafloxacin (STFX), a fluoroquinolone compound, in complicated urinary tract infections (UTI) was investigated in a randomized double-blind comparative study using levofloxacin (LVFX) as a control.<BR>Patients with complicated UTI without indwelling catheters were treated orally 7 days with 50mg b.i.d. of STFX or 100 mg t.i.d. of LVFX. Clinical efficacy was evaluated based on criteria for evaluation ofclinical efficacy of antimicrobial agents on urinary tract infection (third edition).<BR>Patients evaluated numbered 200. Overall clinical efficacy was 96.1%(98/102) in the STFX group and 82.7%(81/98) in the LVFX group. The difference in efficacy was 13.4% and the minimum 90% confidence interval was 6.4%. The noninferiority of STFX efficacy was evaluated against that of LVFX. Strains isolated before dosing numbered 280. Overall microbiological eradication was 96.4%(132/137) in the STFX group and 86.0%(123/143) in the LVFX group. Eradication in the STFX group was significantly higher than that in the LVFX group.<BR>The incidence of adverse reactions was 24.6%(30/122) in the STFX group and 11.6%(14/121) in the LVFX group. The incidence in the STFX group was significantly higher than that in the LVFX group.(X2test: p=0.008). The most common adverse reaction was diarrhea in both groups. All symptoms were mild or moderate.<BR>Results suggest that 50mg b.i.d. of STFX is effective and without significant safety problems in the treatment of complicated UTI.
収録刊行物
-
- 日本化学療法学会雑誌
-
日本化学療法学会雑誌 56 (Supplement1), 81-91, 2008
公益社団法人 日本化学療法学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282681264793216
-
- NII論文ID
- 10021192838
- 130004102790
-
- NII書誌ID
- AN10472127
-
- ISSN
- 18845886
- 13407007
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可